These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34640558)

  • 1. Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.
    Goldman VE; Naguib MN; Vidmar AP
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
    Firkins SA; Chittajallu V; Flora B; Yoo H; Simons-Linares R
    Obes Surg; 2024 May; 34(5):1415-1424. PubMed ID: 38512645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive management of obesity in people with Prader-Willi syndrome.
    Nolan BJ; Proietto J; Sumithran P
    Endocrine; 2022 Jun; 77(1):57-62. PubMed ID: 35524875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
    Song JE; Ko HJ; Kim AS
    Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
    Diene G; Angulo M; Hale PM; Jepsen CH; Hofman PL; Hokken-Koelega A; Ramesh C; Turan S; Tauber M
    J Clin Endocrinol Metab; 2022 Dec; 108(1):4-12. PubMed ID: 36181471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.
    Bonnot O; Cohen D; Thuilleaux D; Consoli A; Cabal S; Tauber M
    Eur J Pediatr; 2016 Jan; 175(1):9-18. PubMed ID: 26584571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.
    Sani E; Prato GD; Zenti MG; Bordugo A; Trombetta M; Bonora E
    Endocr Metab Immune Disord Drug Targets; 2022; 22(10):1053-1057. PubMed ID: 35538810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes.
    Giménez-Palop O; Romero A; Casamitjana L; Pareja R; Rigla M; Caixàs A
    Endocrinol Diabetes Nutr (Engl Ed); 2024 Feb; 71(2):83-87. PubMed ID: 38553173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.
    Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B
    Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358
    [No Abstract]   [Full Text] [Related]  

  • 11. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
    Tan Q; Orsso CE; Deehan EC; Triador L; Field CJ; Tun HM; Han JC; Müller TD; Haqq AM
    Obes Rev; 2020 May; 21(5):e12992. PubMed ID: 31889409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of intranasal oxytocin in patients with Prader-Willi syndrome: A systematic review and meta-analysis.
    Shalma NM; Alsharabasy MA; Taha AM; Alsawareah A; Manirambona E; Ahmed SK; Mohamed MR; Taha NA; Abd-ElGawad M
    Diabetes Metab Syndr; 2023 Feb; 17(2):102711. PubMed ID: 36774885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.
    Ng NBH; Low YW; Rajgor DD; Low JM; Lim YY; Loke KY; Lee YS
    Clin Endocrinol (Oxf); 2022 Feb; 96(2):144-154. PubMed ID: 34448208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prader-Willi Syndrome: Possibilities of Weight Gain Prevention and Treatment.
    Erhardt É; Molnár D
    Nutrients; 2022 May; 14(9):. PubMed ID: 35565916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.
    Gasoyan H; Pfoh ER; Schulte R; Sullivan E; Le P; Rothberg MB
    Diabetes Obes Metab; 2024 May; 26(5):1687-1696. PubMed ID: 38287140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Treatment of Obesity in Reproductive Aged Women.
    Nuako A; Tu L; Reyes KJC; Chhabria SM; Stanford FC
    Curr Obstet Gynecol Rep; 2023 Jun; 12(2):138-146. PubMed ID: 37427372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prader-Willi Syndrome, Management of Impulsivity, and Hyperphagia in an Adolescent.
    Puri MR; Sahl R; Ogden S; Malik S
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):403-4. PubMed ID: 27028699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.
    Ahmad NN; Robinson S; Kennedy-Martin T; Poon JL; Kan H
    Obes Rev; 2021 Nov; 22(11):e13326. PubMed ID: 34423889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.